Provenance Record

Excellent, carefully-hedged clinical News piece (732 words) on the Phase III OPTIMA result. Distinguishes the per-protocol primary analysis from the low-ROR subgroup and is transparent that conference data precede any journal publication.

All 3 snapshots read from disk (HTTP 200). source-0 (The ASCO Post) confirms verbatim: 4,429 patients, 2,214-patient test arm, Abstract 500, 68%, ROR >60 chemo / '60 or less' skip, age 40+, ER+/HER2-, 0-9 nodes, 30 mm, HR 0.99 (90% CI 0.81-1.20; noninferiority P = .013), 3.9-year median, the Stein/MacPherson leads with titles, the UCL/NIHR/Veracyte funders, and both the Stein and MacPherson quotes. source-1 (OncoDaily) confirms the per-protocol 91.8% vs 90.3% IBCFS, HR 1.03 (90% CI 0.85-1.25), P 0.006, the 94.8%/93.6% low-ROR subgroup, and 68%. source-2 (CancerNetwork) confirms the MinhTri Nguyen (Ohio State) preview attribution.

Every statistic traces to the specific outlet it is cited to. The two slightly different IBCFS cuts (OncoDaily's 91.8/90.3, HR 1.03, P 0.006 vs ASCO Post's HR 0.99, P .013) are each attributed to a single outlet — no compound citation conflates them — and the article explicitly flags the inter-outlet differences in 'What We Don't Know'. The article's '0.013' and '60 or below' match the source's 'P = .013' and '60 or less' (leading-zero / synonym only). Exemplary handling of a cross-source discrepancy.

High-quality, fully-verified medical submission with disciplined single-outlet attribution of every statistic. APPROVE.